<!DOCTYPE html><html><head><title>R: Mayo Clinic Primary Biliary Cholangitis Data</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.css">
<script type="text/javascript">
const macros = { "\\R": "\\textsf{R}", "\\code": "\\texttt"};
function processMathHTML() {
    var l = document.getElementsByClassName('reqn');
    for (let e of l) { katex.render(e.textContent, e, { throwOnError: false, macros }); }
    return;
}</script>
<script defer src="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.js"
    onload="processMathHTML();"></script>
<link rel="stylesheet" type="text/css" href="R.css" />
</head><body><div class="container"><main>

<table style="width: 100%;"><tr><td>pbc</td><td style="text-align: right;">R Documentation</td></tr></table>

<h2>Mayo Clinic Primary Biliary Cholangitis Data</h2>

<h3>Description</h3>

<p>Primary biliary cholangitis
is an autoimmune disease leading to
destruction of the small bile ducts in the liver.  Progression is
slow but inexhortable, eventually leading to cirrhosis and liver
decompensation.
The condition has been recognised since at least 1851 and was named
&quot;primary biliary cirrhosis&quot; in 1949.
Because cirrhosis is a feature only of advanced disease, a change of
its name to &quot;primary biliary cholangitis&quot; was proposed by patient
advocacy groups in 2014.
</p>
<p>This data is from the Mayo Clinic trial in PBC conducted between 1974
and 1984.  
A total of 424 PBC patients, referred to Mayo Clinic during that ten-year
interval, met eligibility criteria for the randomized placebo controlled
trial of the drug D-penicillamine.  The first 312 cases in the data set
participated in the randomized trial and contain largely complete data.  The
additional 112 cases did not participate in the clinical trial, but consented
to have basic measurements recorded and to be followed for survival.  Six of
those cases were lost to follow-up shortly after diagnosis, so the data here
are on an additional 106 cases as well as the 312 randomized participants.
</p>
<p>A nearly identical data set found in appendix D of Fleming and Harrington;
this version has fewer missing values.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>pbc
data(pbc, package="survival")
</code></pre>


<h3>Format</h3>


<table>
<tr>
 <td style="text-align: left;">
    age:</td><td style="text-align: left;"> in years</td>
</tr>
<tr>
 <td style="text-align: left;">
    albumin:</td><td style="text-align: left;"> serum albumin (g/dl)</td>
</tr>
<tr>
 <td style="text-align: left;">
    alk.phos:</td><td style="text-align: left;"> alkaline phosphotase (U/liter)</td>
</tr>
<tr>
 <td style="text-align: left;">
    ascites:</td><td style="text-align: left;"> presence of ascites </td>
</tr>
<tr>
 <td style="text-align: left;">
    ast:</td><td style="text-align: left;"> aspartate aminotransferase, once called SGOT (U/ml)</td>
</tr>
<tr>
 <td style="text-align: left;">
    bili:</td><td style="text-align: left;"> serum bilirunbin (mg/dl)</td>
</tr>
<tr>
 <td style="text-align: left;">
    chol:</td><td style="text-align: left;"> serum cholesterol (mg/dl)</td>
</tr>
<tr>
 <td style="text-align: left;">
    copper:</td><td style="text-align: left;"> urine copper (ug/day)</td>
</tr>
<tr>
 <td style="text-align: left;">
    edema:</td><td style="text-align: left;"> 0 no edema, 0.5 untreated or successfully treated</td>
</tr>
<tr>
 <td style="text-align: left;">
    </td><td style="text-align: left;"> 1 edema despite diuretic therapy</td>
</tr>
<tr>
 <td style="text-align: left;">
    hepato:</td><td style="text-align: left;"> presence of hepatomegaly or enlarged liver</td>
</tr>
<tr>
 <td style="text-align: left;">
    id:</td><td style="text-align: left;"> case number</td>
</tr>
<tr>
 <td style="text-align: left;">
    platelet:</td><td style="text-align: left;"> platelet count</td>
</tr>
<tr>
 <td style="text-align: left;">
    protime:</td><td style="text-align: left;"> standardised blood clotting time</td>
</tr>
<tr>
 <td style="text-align: left;">
    sex:</td><td style="text-align: left;"> m/f</td>
</tr>
<tr>
 <td style="text-align: left;">
    spiders:</td><td style="text-align: left;"> blood vessel malformations in the skin</td>
</tr>
<tr>
 <td style="text-align: left;">
    stage:</td><td style="text-align: left;"> histologic stage of disease (needs biopsy)</td>
</tr>
<tr>
 <td style="text-align: left;">
    status:</td><td style="text-align: left;"> status at endpoint, 0/1/2 for censored, transplant, dead</td>
</tr>
<tr>
 <td style="text-align: left;">
    time: </td><td style="text-align: left;"> number of days between registration and the earlier of death,</td>
</tr>
<tr>
 <td style="text-align: left;">
       </td><td style="text-align: left;"> transplantion, or study analysis in July, 1986</td>
</tr>
<tr>
 <td style="text-align: left;">
    trt:</td><td style="text-align: left;"> 1/2/NA for D-penicillmain, placebo, not randomised</td>
</tr>
<tr>
 <td style="text-align: left;">
    trig:</td><td style="text-align: left;"> triglycerides (mg/dl)</td>
</tr>
<tr>
 <td style="text-align: left;">
  </td>
</tr>

</table>



<h3>Source</h3>

<p>T Therneau and P Grambsch (2000),
<em>Modeling Survival Data: Extending the Cox Model</em>,
Springer-Verlag, New York.
ISBN: 0-387-98784-3.
</p>


<h3>See Also</h3>

<p><code>pbcseq</code></p>

</main>

</div>
</body></html>
